As insurers minimal protection of behavioral discomfort therapy, biopharmaceutical brands sensed an opportunity. Pharmaceutical innovation propagated extended-launch formulations, transdermal patches, nasal sprays, and oral dissolving strips. Health care product suppliers drove a proliferation of novel ache-modulating implants. By 2000, Persistent